What is Isomorphic Labs' IsoDD platform and how does it work?

IsoDD (Isomorphic Labs Drug Design Engine) predicts induced-fit interactions where proteins change shape upon ligand binding, and identifies cryptic binding pockets—hidden binding sites on proteins that become visible when a specific molecule interacts with them. The platform is versatile across multiple drug modalities, including de novo antibodies and other large biologics, and expands the druggable landscape beyond traditionally known binding pockets revealed by structural biology.

Why is pharma investing in AI platforms rather than individual drug assets?

According to Isomorphic Labs president Max Jaderberg, the company is building a general design engine applicable to any disease area, decoupled from developing therapeutics for a particular indication or target. Investors and pharma partners believe that end-to-end AI platforms driven by models and compute, combined with large integrated datasets spanning multiple biological dimensions, enable more powerful models of biological complexity for programmable therapeutics guided by prediction and rational design.

What is the concern about AI drug discovery valuations?

Biotech and AI analyst Andrii Buvailo suggests that while investors may have deep conviction in Isomorphic's platform and pharma partnerships, the alternative scenario is that the AI drug discovery valuation cycle has fully decoupled from clinical proof, meaning capital is chasing computational promise on its own terms rather than waiting for clinical data to validate the approach.

AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIJul 6, 2026Jul 7, 2026, 06:31 JST

Pharma Giants Back AI Drug Discovery with Billions as Clinical Proof Lags

Send on LINE

3 Key Points

What happened
Isomorphic Labs raised $2.1 billion（約3400億円） in May led by Thrive Capital and secured major partnerships with Novartis, Eli Lilly, and Johnson & Johnson. The company's IsoDD platform predicts protein-ligand interactions and identifies cryptic binding pockets to expand the druggable landscape. Separately, Genesis Molecular AI and Incyte announced an expanded collaboration worth potentially over $1 billion（約1600億円）, while Chai Discovery licensed its Chai-3 antibody design model to Pfizer, and Inceptive partnered with Alnylam Pharmaceuticals in a deal worth up to $2 billion（約3200億円） with $30 million（約48億円） upfront.
Why it matters
The investments reflect conviction in AI platforms and proprietary datasets as the foundation of drug discovery, even though few AI-designed drugs have reached the clinic. For pharma companies, embedding AI-driven workflows into R&D pipelines—using foundation models trained on internal genomics, transcriptomics, and proteomics data—may unlock previously intractable problems like neurological disease and accelerate candidate nomination timelines. However, commentators note the valuation cycle may have decoupled from clinical proof, meaning capital is chasing computational promise before real-world efficacy is proven.
What to watch
Foresite-backed Xaira Therapeutics, which launched in 2024 with more than $1 billion（約1600億円） in funding, is building virtual cell models to advance target discovery. Inductive Bio gained external validation in February by placing first in the OpenADMET-ExpansionRx blind challenge for predicting drug compound properties. The key differentiator for investors is whether AI can solve previously unsolvable problems and change the pace or probability of clinical success, not just model accuracy alone.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Get news like this every morning, free

Context & Analysis

The pharmaceutical industry's shift toward billion-dollar AI platform investments marks a departure from traditional drug discovery funding models. Rather than backing single assets or compounds, pharma giants and venture firms are now betting on integrated discovery engines—built by companies like Isomorphic Labs, Inceptive, and Inductive Bio—that combine AI models with proprietary datasets and computational workflows. This infrastructure-first approach reflects a belief that AI can unlock previously intractable problems: Insitro's partnership with Bristol Myers Squibb targets amyotrophic lateral sclerosis (ALS), Inceptive is developing foundation models for RNA-based therapies, and Inductive Bio's virtual lab technologies aim to surface risks earlier and accelerate candidate nomination timelines.

Yet the sector faces a notable credibility gap. Commentators have flagged that few AI-designed drugs have actually reached the clinic, and some analysts worry the industry's valuation cycle may have decoupled from clinical proof. Investors and operators counter that differentiation lies in solving previously unsolvable problems and owning business outcomes—not just model accuracy—and point to early validation signals like Inductive Bio's first-place finish in the OpenADMET-ExpansionRx benchmarking competition. The race is on to prove that AI-accelerated discovery translates into higher probability and faster timelines for clinical success; until then, capital continues to flow on the strength of platform design and pharma partnerships alone.

FAQ

What is Isomorphic Labs' IsoDD platform and how does it work?: IsoDD (Isomorphic Labs Drug Design Engine) predicts induced-fit interactions where proteins change shape upon ligand binding, and identifies cryptic binding pockets—hidden binding sites on proteins that become visible when a specific molecule interacts with them. The platform is versatile across multiple drug modalities, including de novo antibodies and other large biologics, and expands the druggable landscape beyond traditionally known binding pockets revealed by structural biology.
Why is pharma investing in AI platforms rather than individual drug assets?: According to Isomorphic Labs president Max Jaderberg, the company is building a general design engine applicable to any disease area, decoupled from developing therapeutics for a particular indication or target. Investors and pharma partners believe that end-to-end AI platforms driven by models and compute, combined with large integrated datasets spanning multiple biological dimensions, enable more powerful models of biological complexity for programmable therapeutics guided by prediction and rational design.
What is the concern about AI drug discovery valuations?: Biotech and AI analyst Andrii Buvailo suggests that while investors may have deep conviction in Isomorphic's platform and pharma partnerships, the alternative scenario is that the AI drug discovery valuation cycle has fully decoupled from clinical proof, meaning capital is chasing computational promise on its own terms rather than waiting for clinical data to validate the approach.

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.